Glecaprevir and pibrentasvir: all 46 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIVRecruitingNCT07040319Phase 1/2
• Glecaprevir/Pibrentasvir for Post-traumatic Stress DisorderRecruitingNCT05637879Phase 2/3
• Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvirRecruitingNCT03855917Phase 4
• Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)CompletedNCT04903626Phase 3Results posted
• Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic DonorsCompletedNCT04575896Phase 4Results posted
• QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/PibrentasvirTerminatedNCT04515797Phase 4Results posted
• Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus InfectionCompletedNCT04042740Phase 2Results posted
• Utilization of Hepatitis C Positive Kidneys in Negative RecipientsCompletedNCT03801707Phase 2/3Results posted
• Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive DonorsCompletedNCT03627299Phase 4Results posted
• Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung TransplantTerminatedNCT03625687Phase 4Results posted
• A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With MavyretCompletedNCT03523871Phase 2Results posted
• Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-InfectionCompletedNCT03235349Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-InfectionCompletedNCT03222583Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 InfectionCompletedNCT03219216Phase 3Results posted
• Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1CompletedNCT03212521Phase 3Results posted
• Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C PatientsCompletedNCT03117569Phase 3Results posted
• A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated CirrhosisCompletedNCT03089944Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal ImpairmentCompletedNCT03069365Phase 3Results posted
• A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT03067129Phase 2/3Results posted
• A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 InfectionCompletedNCT02966795Phase 3Results posted
• Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis CCompletedNCT02946034Phase 4Results posted
• Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical StudyCompletedNCT02939989Phase 3Results posted
• Transplanting Hepatitis C Kidneys Into Negative Kidney RecipientsCompletedNCT02743897Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)CompletedNCT02738138Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus InfectionCompletedNCT02723084Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02707952Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)CompletedNCT02692703Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 InfectionCompletedNCT02651194Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated CirrhosisCompletedNCT02642432Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 InfectionCompletedNCT02640482Phase 3Results posted
• A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 InfectionCompletedNCT02640157Phase 3Results posted
• The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)CompletedNCT02636595Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 InfectionCompletedNCT02604017Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing TherapyCompletedNCT02446717Phase 2/3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 InfectionCompletedNCT02243293Phase 2/3Results posted
• Glecaprevir/Pibrentasvir for the Treatment of PTSDCompletedNCT05446857Phase 2/3
• Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSPCompletedNCT05108935Not applicable
• A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney TransplantationCompletedNCT04682509Early Phase 1
• Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis AccessWithdrawnNCT04614142Phase 4
• Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ DonorCompletedNCT04596475Phase 1/2
• A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant RecipientsActive, not recruitingNCT04508907Phase 4
• Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)WithdrawnNCT04235049Phase 4
• Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney TransplantWithdrawnNCT03623568Phase 4
• A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgramsCompletedNCT03492112Not applicable
• Toward Elimination of Hepatitis C Virus (HCV): A Pilot StudyStatus unknownNCT03364725Phase 4
• Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/PCompletedNCT02634008Phase 3

← Glecaprevir and pibrentasvir overview